Results 101 to 110 of about 1,201,269 (362)

A Decision Making Approach for Chemotherapy Planning based on Evolutionary Processing [PDF]

arXiv, 2023
The problem of chemotherapy treatment optimization can be defined in order to minimize the size of the tumor without endangering the patient's health; therefore, chemotherapy requires to achieve a number of objectives, simultaneously. For this reason, the optimization problem turns to a multi-objective problem.
arxiv  

Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

British Journal of Surgery, 2018
Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival ...
T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka, Y. Kaneoka, M. Yamamoto, Y. Ambo, Y. Shimizu, F. Ozawa, A. Fukutomi, M. Ando, Y. Nimura, M. Nagino, S. Nakamori, T. Ajiki, H. Baba, R. Yamaguchi, M. Kawai, H. Nagano, F. Miura, T. Arai, Y. Nishiwaki, S. Kawasaki, H. Shinchi, M. Shimoda, Y. Yamamoto, I. Endo, S. Isaji, T. Otsubo, S. Ishihara, T. Takahara, M. Shimada, M. Unno, M. Imamura, N. Ohkochi, Y. Murakami, J. Fujimoto, S. Ikuta, Y. Fujino, M. Uebayashi, S. Ishiyama, N. Takakura, Y. Kumamoto, T. Kato, I. Yoshioka, S. Uemoto, K. Yanaga   +48 more
semanticscholar   +1 more source

Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment [PDF]

International Journal of Immunopathology, Allergology, Infectology 2010, #4: P. 42-51, 2011
Improvement of anti-tumor biotherapy effectiveness by modification of immune response with histamine H2 receptor Cimetidinum (CM) was studied using the experimental murine model of B16 F10 melanoma in vivo. It is shown that skin melanoma biotherapy by antitumor whole-cell GM-CSF-producing vaccine with the addition of CM (in dose of 25 mg/kg, daily for ...
arxiv  

Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.

JAMA Oncology, 2016
IMPORTANCE Adjuvant chemotherapy improves outcomes of patients with breast cancer. However, the optimal timing of chemotherapy initiation is unknown. Delayed administration can decrease the benefit of cytotoxic systemic therapies. OBJECTIVE To identify
M. Chávez-MacGregor, C. Clarke, D. Lichtensztajn, S. Giordano   +3 more
semanticscholar   +1 more source

Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single‐center retrospective study in China

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To assess the predictive capability of CT radiomics features for early recurrence (ER) of pancreatic ductal adenocarcinoma (PDAC). Methods Postoperative PDAC patients were retrospectively selected, all of whom had undergone preoperative CT imaging and surgery. Both patients with resectable or borderline‐resectable pancreatic cancer met
Xinze Du, Yongsu Ma, Kexin Wang, Xiejian Zhong, Jianxin Wang, Xiaodong Tian, Xiaoying Wang, Yinmo Yang   +7 more
wiley   +1 more source

Bayesian Nonparametric Cost-Effectiveness Analyses: Causal Estimation and Adaptive Subgroup Discovery [PDF]

arXiv, 2020
Cost-effectiveness analyses (CEAs) are at the center of health economic decision making. While these analyses help policy analysts and economists determine coverage, inform policy, and guide resource allocation, they are statistically challenging for several reasons. Cost and effectiveness are correlated and follow complex joint distributions which are
arxiv  

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Annals of Clinical and Translational Neurology, EarlyView.
Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ...
Young Nam Kwon, Nanthaya Tisavipat, Yong Guo, Stephanie B. Syc‐Mazurek, Ji Yeon Han, Jun‐Soon Kim, Kyomin Choi, Seong‐il Oh, Seok‐Jin Choi, Eunhee Sohn, Jeeyoung Oh, Seung Woo Kim, Ha Young Shin, Byung Chan Lim, Byoung Joon Kim, Kyung Seok Park, Jung‐Joon Sung, Se Hoon Kim, Sung‐Hye Park, Anastasia Zekeridou, Claudia F. Lucchinetti, Sean J. Pittock, John J. Chen, Eoin P. Flanagan, Sung‐Min Kim   +24 more
wiley   +1 more source

Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer

Therapeutics and Clinical Risk Management, 2015
Katsuhiko Shimizu, Riki Okita, Shinsuke Saisho, Takuro Yukawa, Ai Maeda, Yuji Nojima, Masao Nakata Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Japan Background: Adjuvant chemotherapy after the complete resection of non ...
Shimizu K, Okita R, Saisho S, Yukawa T, Maeda A, Nojima Y, Nakata M   +6 more
doaj  

Localized stomach cancer: Perioperative or postoperative approach? A meta‐analysis of phase III studies

JGH Open, 2022
Background and Aim Despite the development and standardization of surgical techniques in the treatment of localized gastric adenocarcinoma, the loco‐regional and metastatic recurrence rate remains high.
Wala Ben Kridis, Haitham Rejab, Rafik Mzali, Jamel Daoud, Afef Khanfir   +4 more
doaj   +1 more source

Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma.

Journal of Oncology Practice, 2017
The decision to treat a patient with stage II colon cancer with adjuvant chemotherapy can be challenging. Although the benefit of treatment is clear in most patients with stage III disease, the decision to provide chemotherapy after surgical resection in
Joseph Kannarkatt, Joe Joseph, P. Kurniali, A. Al-Janadi, B. Hrinczenko   +4 more
semanticscholar   +1 more source